Optimizing Anti-PD-1 Immunotherapy for Cancer Treatment

Strategic Insights -

Researchers at the University of Porto have conducted a study on the pharmacokinetics of anti-PD-1 antibodies, such as nivolumab, pembrolizumab, and cemiplimab, and explored their pharmacokinetic-pharmacodynamic relationships. The study highlights the importance of baseline clearance and its reduction during therapy as dynamic biomarkers for guiding individualized dosing strategies. The researchers propose a shift from traditional weight-based dosing toward adaptive dosing and therapeutic drug monitoring, which could improve outcomes and reduce toxicity.

Key Takeaways:

  • The study found that anti-PD-1 therapies have transformed cancer treatment by restoring antitumor T cell activity, but variability in treatment response and immune-related adverse events necessitates therapeutic optimization.
  • The research identified baseline clearance and its reduction during therapy as important dynamic biomarkers for guiding individualized dosing strategies.
  • The study discussed established biomarkers for anti-PD-1 therapies, including tumor PD-L1 expression and immune cell signatures, and their relevance for patient stratification.
  • The researchers proposed a shift from traditional weight-based dosing toward adaptive dosing and therapeutic drug monitoring to improve outcomes and reduce toxicity.
  • The study concluded that optimizing anti-PD-1 therapy through PK-PD insights and biomarker integration holds promise for improving outcomes and reducing toxicity.
  • The researchers emphasized the need for future research to validate PK-based approaches and develop robust algorithms for tailored cancer treatment.

Statistics:

  • The study examined the pharmacokinetics of anti-PD-1 antibodies, including nivolumab, pembrolizumab, and cemiplimab.
  • The research found that baseline clearance and its reduction during therapy emerged as important dynamic biomarkers for guiding individualized dosing strategies.
  • The study concluded that the inclusion of clearance-based biomarkers into therapeutic models represents a key step toward individualized, dynamic immunotherapy.

Sources:

  • Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring. Cancers, 2025;17(19):3262.
  • University of Porto. Laboratorio de Farmacologia, Departamento de Ciencias do Medicamento, Faculdade de Farmacia.
  • Alexandrina Fernandes, Joaquim Faria Monteiro, Diogo Gavina Tato, Elias Moreira, Ricardo Ribeiro, Henrique Reguengo, Jorge Goncalves, and Paula Fresco. Investigators at University of Porto Target Cancer (Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring). Immunotherapy Weekly. October 29, 2025; p 1977.